Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
Conditions
- Recurrent Bladder Urothelial Carcinoma
- Recurrent Renal Pelvis Urothelial Carcinoma
- Recurrent Ureter Urothelial Carcinoma
- Recurrent Urethral Urothelial Carcinoma
- Stage 0a Bladder Cancer AJCC v8
- Stage 0a Renal Pelvis Cancer AJCC v8
- Stage 0a Ureter Cancer AJCC v8
- Stage 0a Urethral Cancer AJCC v8
- Stage 0is Bladder Cancer AJCC v8
- Stage 0is Renal Pelvis Cancer AJCC v8
- Stage 0is Ureter Cancer AJCC v8
- Stage 0is Urethral Cancer AJCC v8
- Stage II Bladder Cancer AJCC v8
- Stage II Renal Pelvis Cancer AJCC v8
- Stage II Ureter Cancer AJCC v8
- Stage II Urethral Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8
Interventions
- DRUG: Erlotinib Hydrochloride
Sponsor
M.D. Anderson Cancer Center
Collaborators